Radiopharmaceutical innovation starts here

Radiopharmaceutical molecules are becoming more innovative and technically demanding. Many of the projects we support are unprecedented and highly specific, which is why we have internalized the most complex stages of chemistry.

Our dedicated team of experts focuses on developing and manufacturing the critical ingredients used in radiopharmaceutical drug formulations. By specializing in innovative molecules, we leverage cutting-edge tools and expertise to accelerate development timelines, particularly through advanced analytical method optimization and robust process design.

Trasis: much more than a CDMO

At Trasis, we are a true innovation partner for the radiopharmaceutical industry. In this short video, Antoine Briffaux, our VP and Head of our Ingredients business line, explains how our in-house expertise in complex chemistry and analytical method optimization helps accelerate development and secure manufacturing.

From concept to controlled manufacturing: two success stories

Trivehexin: developing a robust manufacturing process

Discover how our team designed and scaled the manufacturing process of the Trivehexin macro-structure, navigating complexity to deliver a reproducible, regulatory-ready solution.

FMZ-BPin: proving expertise with a fragile, air-sensitive precursor

Some precursors require a degree of control that exceeds routine development. FMZ-BPin is one of them. Used to produce [¹⁸F]Flumazenil for brain imaging, this boronate reacts to air and humidity and shows a weak direct HPLC signal.

Coming soon

Secure your first batches on our new aseptic fill & finish line

Trasis offers a fully integrated solution that spans the entire radiopharmaceutical lifecycle. Designed for small and medium volumes, full GMP compliance and rapid turnaround, it is a strategic accelerator for early clinical needs and niche radiopharmaceutical products.

Our ready-to-manufacture product catalog

We are pleased to announce the upcoming launch of our catalog of products. The catalog will feature a wide range of high-value compounds. Stay tuned for the official release and discover how our expertise as a CDMO can support your projects from development to commercial supply.

Related contents

We have been named Entrepreneur of the year® 2025!

Trasis simplifies your radiopharmaceutical QC - from batch release to sterility testing